Health
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – Yahoo Finance
Vancouver, British Columbia–(Newsfile Corp. – November 2, 2020) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in…
Vancouver, British Columbia–(Newsfile Corp. – November 2, 2020) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response…
-
General24 hours agoHome of Andrii Yermak, Zelenskyy’s chief of staff, raided by anti-corruption unit
-
Business15 hours agoIs this the best ASX ETF to diversify your portfolio with?
-
General11 hours agoLiberals go back to basics after crawling to year’s end
-
Business16 hours ago3 of the best ASX ETFs to build significant wealth